{"id":27405,"date":"2020-09-28T10:11:26","date_gmt":"2020-09-28T08:11:26","guid":{"rendered":"https:\/\/kymos.com\/news\/kymos-et-prolytic-fusionnent-pour-former-le-groupe-kymos\/"},"modified":"2026-03-04T21:10:26","modified_gmt":"2026-03-04T20:10:26","slug":"kymos-et-prolytic-fusionnent-pour-former-le-groupe-kymos","status":"publish","type":"post","link":"https:\/\/kymos.com\/fr\/news\/kymos-et-prolytic-fusionnent-pour-former-le-groupe-kymos\/","title":{"rendered":"Kymos et Prolytic fusionnent pour devenir Kymos Group"},"content":{"rendered":"<div class=\"fusion-fullwidth fullwidth-box fusion-builder-row-1 fusion-flex-container nonhundred-percent-fullwidth non-hundred-percent-height-scrolling\" style=\"--awb-border-radius-top-left:0px;--awb-border-radius-top-right:0px;--awb-border-radius-bottom-right:0px;--awb-border-radius-bottom-left:0px;--awb-flex-wrap:wrap;\" ><div class=\"fusion-builder-row fusion-row fusion-flex-align-items-flex-start fusion-flex-content-wrap\" style=\"max-width:calc( 1170px + 20px );margin-left: calc(-20px \/ 2 );margin-right: calc(-20px \/ 2 );\"><div class=\"fusion-layout-column fusion_builder_column fusion-builder-column-0 fusion_builder_column_1_1 1_1 fusion-flex-column\" style=\"--awb-bg-blend:overlay;--awb-bg-size:cover;--awb-width-large:100%;--awb-margin-top-large:0px;--awb-spacing-right-large:10px;--awb-margin-bottom-large:0px;--awb-spacing-left-large:10px;--awb-width-medium:100%;--awb-spacing-right-medium:10px;--awb-spacing-left-medium:10px;--awb-width-small:100%;--awb-spacing-right-small:10px;--awb-spacing-left-small:10px;\"><div class=\"fusion-column-wrapper fusion-flex-justify-content-flex-start fusion-content-layout-column\"><div class=\"fusion-text fusion-text-1\"><h3 class=\"\" style=\"--fontsize: 17; line-height: 1.67; --minfontsize: 17;\" data-fontsize=\"17\" data-lineheight=\"28.39px\"><span style=\"font-size: 14pt;\"><strong>Avec l\u2019int\u00e9gration de la CRO allemande au groupe europ\u00e9en, Kymos renforcera son activit\u00e9 sur le march\u00e9 des produits biologiques et des th\u00e9rapies avanc\u00e9es et \u00e9largira son portefeuille de services, tout en proposant trois sites locaux en Europe<\/strong><\/span><\/h3>\n<div class=\"blog-content\">\n<div class=\"field field-name-body field-type-text-with-summary field-label-hidden\">\n<div class=\"field-items\">\n<div class=\"field-item even\">\n<p><span style=\"font-size: 14pt;\"><strong>Barcelone, Espagne, et Francfort, Allemagne, 28 septembre 2020<\/strong> \u2013 <a href=\"https:\/\/kymos.com\/fr\/kymos\/\" data-wpel-link=\"internal\">Kymos S.L<\/a>. et <a href=\"https:\/\/kymos.com\/fr\/prolytic\/\" data-wpel-link=\"internal\">Prolytic GmbH<\/a> annoncent aujourd\u2019hui la finalisation d\u2019une fusion strat\u00e9gique r\u00e9ussie visant \u00e0 int\u00e9grer Prolytic au sein de Kymos Group, afin d\u2019offrir des services \u00e0 valeur ajout\u00e9e aux entreprises biopharmaceutiques du monde entier, avec une solution v\u00e9ritablement paneurop\u00e9enne dans un environnement \u00e9conomique en \u00e9volution rapide. <\/span><\/p>\n<p><span style=\"font-size: 14pt;\">La combinaison des expertises permettra aux entreprises d\u2019\u00e9largir leur portefeuille avec une s\u00e9lection unique de services pour des petites et grandes mol\u00e9cules innovantes, des g\u00e9n\u00e9riques, des biosimilaires, des anticorps, des biomarqueurs, des ADA (anticorps anti-m\u00e9dicament), des ADC (conjugu\u00e9s anticorps-m\u00e9dicament), des hormones, des enzymes et des acides nucl\u00e9iques. Elles intensifieront \u00e9galement leur activit\u00e9 sur le march\u00e9 des th\u00e9rapies avanc\u00e9es. L\u2019int\u00e9r\u00eat pour les prot\u00e9ines recombinantes et pour les th\u00e9rapies cellulaires et g\u00e9niques avanc\u00e9es est actuellement en plein essor en Europe et dans le monde. Prolytic a acquis une expertise dans les technologies d\u2019ARNm, utilis\u00e9es dans certains des vaccins contre la Covid-19 les plus avanc\u00e9s en cours de d\u00e9veloppement en Europe.   <\/span><\/p>\n<p><span style=\"font-size: 14pt;\">Les deux entreprises, avec Pharmaprogress, une filiale de Kymos Group en Italie, partagent un engagement envers la qualit\u00e9 et une volont\u00e9 d\u2019innovation. Si les clients auront acc\u00e8s \u00e0 une gamme \u00e9largie de services certifi\u00e9s GMP\/GLP et conformes aux BPC (GCP), ils b\u00e9n\u00e9ficieront toujours d\u2019un service sur mesure, personnalis\u00e9 et v\u00e9ritablement flexible, sans \u00e9quivalent parmi les CRO de cette taille. Kymos et Prolytic disposent d\u2019une compr\u00e9hension multidisciplinaire de l\u2019ensemble du processus de d\u00e9veloppement et de fabrication pharmaceutiques, des phases de d\u00e9veloppement et cliniques jusqu\u2019\u00e0 l\u2019approbation finale et aux \u00e9tudes post-commercialisation, offrant s\u00e9curit\u00e9 logistique et fiabilit\u00e9. La fusion se traduira par une am\u00e9lioration de la capacit\u00e9 de l\u2019entreprise \u00e0 r\u00e9pondre encore plus rapidement aux besoins sp\u00e9cifiques de ses clients internationaux.   <\/span><\/p>\n<p><span style=\"font-size: 14pt;\"><em>\u00ab Le march\u00e9 actuel recherche des prestataires de services complets et des solutions tout-en-un. Gr\u00e2ce \u00e0 cette fusion, nous pourrons penser globalement et agir localement, en offrant \u00e0 nos clients un service fiable, digne de confiance et nettement am\u00e9lior\u00e9 \u00bb,<\/em> a d\u00e9clar\u00e9 la Dre Dorothee Krone, directrice g\u00e9n\u00e9rale de Prolytic. <em>\u00ab Les petites et moyennes entreprises se sentent \u00e0 l\u2019aise en travaillant avec nous. Kymos peut nous aider \u00e0 couvrir l\u2019ensemble du cycle des sciences de la vie et nous pouvons d\u00e9sormais proposer une gamme de services bien plus diversifi\u00e9e que tout ce que nous avons pu offrir par le pass\u00e9. \u00bb<\/em><\/span><\/p>\n<p><span style=\"font-size: 14pt;\"><em>\u00ab Les connaissances de Prolytic en mati\u00e8re d\u2019ADN et d\u2019ARN constituent un \u00e9l\u00e9ment scientifique cl\u00e9 du march\u00e9 des services de th\u00e9rapies avanc\u00e9es sur lequel Kymos se positionne \u00bb,<\/em> a d\u00e9clar\u00e9 M. Joan Puig de Dou, PDG de Kymos. <em>\u00ab La fusion nous donne l\u2019opportunit\u00e9 d\u2019\u00e9largir notre offre de services, de renforcer le march\u00e9 \u00e9mergent des th\u00e9rapies et de cr\u00e9er une entreprise multinationale et multidisciplinaire. Nous nous r\u00e9jouissons vivement de cette nouvelle phase de l\u2019histoire de l\u2019entreprise. \u00bb<\/em><\/span><\/p>\n<p><span style=\"font-size: 14pt;\">Avec cette fusion, Kymos dispose d\u00e9sormais de trois sites en Europe : Barcelone (Espagne), Anc\u00f4ne (Italie) et Francfort (Allemagne). Le site italien est le r\u00e9sultat de la fusion de 2016 avec Pharmaprogress SRL. Selon l\u2019accord, les noms des entreprises resteront inchang\u00e9s. Sur le site allemand de Prolytic, l\u2019\u00e9quipe de direction actuelle restera en place, tandis que les effectifs augmenteront. Un plan d\u2019investissement sera mis en \u0153uvre afin d\u2019acqu\u00e9rir des \u00e9quipements de pointe.    <\/span><\/p>\n<p><span style=\"font-size: 14pt;\">Apr\u00e8s avoir renforc\u00e9 sa pr\u00e9sence d\u00e9j\u00e0 importante au sein de l&rsquo;UE, le groupe europ\u00e9en ambitionne de s&rsquo;\u00e9tendre \u00e0 la r\u00e9gion Asie-Pacifique, tout en explorant de nouveaux domaines th\u00e9rapeutiques prometteurs.<\/span><\/p>\n<p><strong style=\"font-size: 14pt; color: var(--body_typography-color); font-family: var(--body_typography-font-family); font-style: var(--body_typography-font-style,normal); letter-spacing: var(--body_typography-letter-spacing);\">\u00c0 propos de Prolytic <\/strong><\/p>\n<p><span style=\"font-size: 14pt;\">Prolytic GmbH est un expert en bioanalyse et en pharmacocin\u00e9tique, avec des capacit\u00e9s de recherche sous contrat sp\u00e9cialis\u00e9es en bioanalyse et en \u00e9valuations pharmacocin\u00e9tiques sous GLP et GCP.<\/span><br \/><span style=\"font-size: 14pt;\">L\u2019entreprise propose une gamme de services sophistiqu\u00e9s de d\u00e9veloppement et de validation de m\u00e9thodes analytiques pour l\u2019analyse et la quantification de petites mol\u00e9cules, de prot\u00e9ines, d\u2019anticorps &amp; d\u2019antig\u00e8nes, d\u2019ADA (anticorps anti-m\u00e9dicament), de biomarqueurs &amp; de biosimilaires, ainsi que d\u2019enzymes intactes, de m\u00eame que l\u2019analyse d\u2019\u00e9chantillons pour des \u00e9tudes pr\u00e9cliniques et cliniques. Prolytic peut r\u00e9aliser des analyses qualitatives ou quantitatives de m\u00e9dicaments et de m\u00e9tabolites dans le sang, le plasma, l\u2019urine, les tissus ou d\u2019autres matrices biologiques. En outre, elle peut \u00e9galement effectuer des \u00e9valuations pharmacocin\u00e9tiques compartimentales et non compartimentales. En tant qu\u2019innovateur, Prolytic est un leader des projets de coop\u00e9ration en recherche financ\u00e9s par l\u2019\u00c9tat dans le domaine du d\u00e9veloppement de biomarqueurs ARN et des th\u00e9rapies avanc\u00e9es.   <\/span><br \/><span style=\"font-size: 14pt;\">Cr\u00e9\u00e9e en 2002 et bas\u00e9e \u00e0 Francfort, Prolytic compte 17 collaborateurs et 1\u202f000 m\u00e8tres carr\u00e9s d\u2019instrumentation de pointe.<\/span><\/p>\n<p><span style=\"font-size: 18.6667px;\"><a href=\"https:\/\/kymos.com\/fr\/prolytic\/\" data-wpel-link=\"internal\">kymos.com\/prolytic<\/a><\/span><\/p>\n<p><span style=\"font-size: 14pt;\"><strong>\u00c0 propos de Kymos<\/strong><\/span><br \/><span style=\"font-size: 14pt;\">Kymos S.L. est un leader mondial et l\u2019un des dix principaux prestataires mondiaux de services de tests de biosimilaires, avec des ann\u00e9es d\u2019exp\u00e9rience dans les produits biologiques, les petites mol\u00e9cules et des services complets \u00e0 la fois en CMC et en bioanalyse. Organisation europ\u00e9enne de laboratoire sous contrat sp\u00e9cialis\u00e9e en bioanalyse et en CMC, certifi\u00e9e GLP\/GMP, conforme aux BPC (GCP) et inspect\u00e9e par l\u2019EMA et la FDA, Kymos r\u00e9alise des \u00e9tudes compl\u00e8tes de bio\u00e9quivalence, y compris des biowaivers pour les formes pharmaceutiques topiques (DP), la bioanalyse de petites &amp; grandes mol\u00e9cules, les ADA, ainsi que des tests de lib\u00e9ration de lots pour des essais pr\u00e9cliniques &amp; cliniques en Europe. Kymos propose \u00e9galement des services CMC pour le d\u00e9veloppement de m\u00e9thodes, la caract\u00e9risation, la comparabilit\u00e9 des biosimilaires, ainsi que des ann\u00e9es d\u2019exp\u00e9rience aupr\u00e8s de clients biopharmaceutiques dans le monde entier.  <\/span><br \/><span style=\"font-size: 14pt;\">Cr\u00e9\u00e9e en 2001 et dont le si\u00e8ge est \u00e0 Barcelone, Kymos compte 110 collaborateurs et 3\u202f000 m2 d\u2019installations, dot\u00e9es d\u2019instruments haut de gamme. La filiale italienne compte 20 collaborateurs suppl\u00e9mentaires et environ 1\u202f000 m2 d\u2019installations. Le chiffre d\u2019affaires cumul\u00e9 des trois entreprises devrait d\u00e9passer 13 M\u20ac (15,1 M$) en 2020.  <\/span><br \/><span style=\"font-size: 14pt;\"><a href=\"https:\/\/kymos.com\/fr\/\" data-wpel-link=\"internal\">Kymos<\/a><\/span><\/p>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div><\/div><\/div><\/div><\/div>\n","protected":false},"excerpt":{"rendered":"","protected":false},"author":6,"featured_media":27407,"comment_status":"closed","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[260,258],"tags":[],"class_list":["post-27405","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-groupe-kymos","category-nouvelles"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Kymos et Prolytic fusionnent pour devenir Kymos Group | Kymos<\/title>\n<meta name=\"description\" content=\"Kymos S.L. et Prolytic GmbH annoncent la r\u00e9ussite d\u2019une fusion strat\u00e9gique visant \u00e0 int\u00e9grer Prolytic au sein de Kymos Group.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/kymos.com\/fr\/news\/kymos-et-prolytic-fusionnent-pour-former-le-groupe-kymos\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Kymos et Prolytic fusionnent pour devenir Kymos Group | Kymos\" \/>\n<meta property=\"og:description\" content=\"Kymos S.L. et Prolytic GmbH annoncent la r\u00e9ussite d\u2019une fusion strat\u00e9gique visant \u00e0 int\u00e9grer Prolytic au sein de Kymos Group.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/kymos.com\/fr\/news\/kymos-et-prolytic-fusionnent-pour-former-le-groupe-kymos\/\" \/>\n<meta property=\"og:site_name\" content=\"Kymos\" \/>\n<meta property=\"article:published_time\" content=\"2020-09-28T08:11:26+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-03-04T20:10:26+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/kymos.com\/wp-content\/uploads\/2021\/11\/2020-09-28-Kymos-and-Prolytic-merge_srt-e1658232445349.png\" \/>\n\t<meta property=\"og:image:width\" content=\"900\" \/>\n\t<meta property=\"og:image:height\" content=\"494\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Joan Puig de Dou\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@KymosGroup\" \/>\n<meta name=\"twitter:site\" content=\"@KymosGroup\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"Joan Puig de Dou\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"6 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/kymos.com\\\/fr\\\/news\\\/kymos-et-prolytic-fusionnent-pour-former-le-groupe-kymos\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/kymos.com\\\/fr\\\/news\\\/kymos-et-prolytic-fusionnent-pour-former-le-groupe-kymos\\\/\"},\"author\":{\"name\":\"Joan Puig de Dou\",\"@id\":\"https:\\\/\\\/kymos.com\\\/fr\\\/#\\\/schema\\\/person\\\/264c93ce9dcf43caa9d634aeafab965c\"},\"headline\":\"Kymos et Prolytic fusionnent pour devenir Kymos Group\",\"datePublished\":\"2020-09-28T08:11:26+00:00\",\"dateModified\":\"2026-03-04T20:10:26+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/kymos.com\\\/fr\\\/news\\\/kymos-et-prolytic-fusionnent-pour-former-le-groupe-kymos\\\/\"},\"wordCount\":1236,\"image\":{\"@id\":\"https:\\\/\\\/kymos.com\\\/fr\\\/news\\\/kymos-et-prolytic-fusionnent-pour-former-le-groupe-kymos\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/kymos.com\\\/wp-content\\\/uploads\\\/2021\\\/11\\\/2020-09-28-Kymos-and-Prolytic-merge_srt-e1658232445349.png\",\"articleSection\":[\"Kymos Group\",\"Nouvelles\"],\"inLanguage\":\"fr-FR\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/kymos.com\\\/fr\\\/news\\\/kymos-et-prolytic-fusionnent-pour-former-le-groupe-kymos\\\/\",\"url\":\"https:\\\/\\\/kymos.com\\\/fr\\\/news\\\/kymos-et-prolytic-fusionnent-pour-former-le-groupe-kymos\\\/\",\"name\":\"Kymos et Prolytic fusionnent pour devenir Kymos Group | Kymos\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/kymos.com\\\/fr\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/kymos.com\\\/fr\\\/news\\\/kymos-et-prolytic-fusionnent-pour-former-le-groupe-kymos\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/kymos.com\\\/fr\\\/news\\\/kymos-et-prolytic-fusionnent-pour-former-le-groupe-kymos\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/kymos.com\\\/wp-content\\\/uploads\\\/2021\\\/11\\\/2020-09-28-Kymos-and-Prolytic-merge_srt-e1658232445349.png\",\"datePublished\":\"2020-09-28T08:11:26+00:00\",\"dateModified\":\"2026-03-04T20:10:26+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/kymos.com\\\/fr\\\/#\\\/schema\\\/person\\\/264c93ce9dcf43caa9d634aeafab965c\"},\"description\":\"Kymos S.L. et Prolytic GmbH annoncent la r\u00e9ussite d\u2019une fusion strat\u00e9gique visant \u00e0 int\u00e9grer Prolytic au sein de Kymos Group.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/kymos.com\\\/fr\\\/news\\\/kymos-et-prolytic-fusionnent-pour-former-le-groupe-kymos\\\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/kymos.com\\\/fr\\\/news\\\/kymos-et-prolytic-fusionnent-pour-former-le-groupe-kymos\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/kymos.com\\\/fr\\\/news\\\/kymos-et-prolytic-fusionnent-pour-former-le-groupe-kymos\\\/#primaryimage\",\"url\":\"https:\\\/\\\/kymos.com\\\/wp-content\\\/uploads\\\/2021\\\/11\\\/2020-09-28-Kymos-and-Prolytic-merge_srt-e1658232445349.png\",\"contentUrl\":\"https:\\\/\\\/kymos.com\\\/wp-content\\\/uploads\\\/2021\\\/11\\\/2020-09-28-Kymos-and-Prolytic-merge_srt-e1658232445349.png\",\"width\":900,\"height\":494,\"caption\":\"Kymos and Prolytic\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/kymos.com\\\/fr\\\/news\\\/kymos-et-prolytic-fusionnent-pour-former-le-groupe-kymos\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/kymos.com\\\/fr\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Kymos et Prolytic fusionnent pour devenir Kymos Group\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/kymos.com\\\/fr\\\/#website\",\"url\":\"https:\\\/\\\/kymos.com\\\/fr\\\/\",\"name\":\"Kymos Group\",\"description\":\"Kymos Group\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/kymos.com\\\/fr\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/kymos.com\\\/fr\\\/#\\\/schema\\\/person\\\/264c93ce9dcf43caa9d634aeafab965c\",\"name\":\"Joan Puig de Dou\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/263d7ff1c7891f5821a5075a1a362a1e513db5931dc882455e887fe1c1ccf924?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/263d7ff1c7891f5821a5075a1a362a1e513db5931dc882455e887fe1c1ccf924?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/263d7ff1c7891f5821a5075a1a362a1e513db5931dc882455e887fe1c1ccf924?s=96&d=mm&r=g\",\"caption\":\"Joan Puig de Dou\"},\"description\":\"Active in the pharmaceutical marketing for over 30 years President of CataloniaBIO&amp;HealthTech CEO and Qualified Person at Kymos Leader of Kymos team, guaranteeing a trustable, ethical and scientific correct editorial publications. Experience Joan Puig de Dou started his career at Laboratorios Menarini first as scientist later as Qualified Person and finally as Operations General Manager. 2010 he entered Kymos where he became CEO in 2015. 2022 Joan Puig de Dou was elected as president of CataloniaBio&amp;HealthTech to represent the Catalonian biotech industry nationally and internationally. Expertise Joan Puig de Dou has extensive experience in writing scientific content adopting a didactic approach that fits any reader\u2019s level of expertise. He publishes regularely on Kymos\u2019 webpage, social media and in the specialized press. Education He graduated from Universitat de Barcelona as Pharmacist and from IESE Business School\u2019s Programa Diecci\u00f3n General (PDG) Want to know him better? Read his interview in PharmaBoardrooom in January 2019 and more about his presidency of CataloniaBio at Parc Sc\u00edentific de Barcelona.\",\"url\":\"https:\\\/\\\/kymos.com\\\/fr\\\/news\\\/author\\\/joan-puig-de-dou\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Kymos et Prolytic fusionnent pour devenir Kymos Group | Kymos","description":"Kymos S.L. et Prolytic GmbH annoncent la r\u00e9ussite d\u2019une fusion strat\u00e9gique visant \u00e0 int\u00e9grer Prolytic au sein de Kymos Group.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/kymos.com\/fr\/news\/kymos-et-prolytic-fusionnent-pour-former-le-groupe-kymos\/","og_locale":"fr_FR","og_type":"article","og_title":"Kymos et Prolytic fusionnent pour devenir Kymos Group | Kymos","og_description":"Kymos S.L. et Prolytic GmbH annoncent la r\u00e9ussite d\u2019une fusion strat\u00e9gique visant \u00e0 int\u00e9grer Prolytic au sein de Kymos Group.","og_url":"https:\/\/kymos.com\/fr\/news\/kymos-et-prolytic-fusionnent-pour-former-le-groupe-kymos\/","og_site_name":"Kymos","article_published_time":"2020-09-28T08:11:26+00:00","article_modified_time":"2026-03-04T20:10:26+00:00","og_image":[{"width":900,"height":494,"url":"https:\/\/kymos.com\/wp-content\/uploads\/2021\/11\/2020-09-28-Kymos-and-Prolytic-merge_srt-e1658232445349.png","type":"image\/png"}],"author":"Joan Puig de Dou","twitter_card":"summary_large_image","twitter_creator":"@KymosGroup","twitter_site":"@KymosGroup","twitter_misc":{"\u00c9crit par":"Joan Puig de Dou","Dur\u00e9e de lecture estim\u00e9e":"6 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/kymos.com\/fr\/news\/kymos-et-prolytic-fusionnent-pour-former-le-groupe-kymos\/#article","isPartOf":{"@id":"https:\/\/kymos.com\/fr\/news\/kymos-et-prolytic-fusionnent-pour-former-le-groupe-kymos\/"},"author":{"name":"Joan Puig de Dou","@id":"https:\/\/kymos.com\/fr\/#\/schema\/person\/264c93ce9dcf43caa9d634aeafab965c"},"headline":"Kymos et Prolytic fusionnent pour devenir Kymos Group","datePublished":"2020-09-28T08:11:26+00:00","dateModified":"2026-03-04T20:10:26+00:00","mainEntityOfPage":{"@id":"https:\/\/kymos.com\/fr\/news\/kymos-et-prolytic-fusionnent-pour-former-le-groupe-kymos\/"},"wordCount":1236,"image":{"@id":"https:\/\/kymos.com\/fr\/news\/kymos-et-prolytic-fusionnent-pour-former-le-groupe-kymos\/#primaryimage"},"thumbnailUrl":"https:\/\/kymos.com\/wp-content\/uploads\/2021\/11\/2020-09-28-Kymos-and-Prolytic-merge_srt-e1658232445349.png","articleSection":["Kymos Group","Nouvelles"],"inLanguage":"fr-FR"},{"@type":"WebPage","@id":"https:\/\/kymos.com\/fr\/news\/kymos-et-prolytic-fusionnent-pour-former-le-groupe-kymos\/","url":"https:\/\/kymos.com\/fr\/news\/kymos-et-prolytic-fusionnent-pour-former-le-groupe-kymos\/","name":"Kymos et Prolytic fusionnent pour devenir Kymos Group | Kymos","isPartOf":{"@id":"https:\/\/kymos.com\/fr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/kymos.com\/fr\/news\/kymos-et-prolytic-fusionnent-pour-former-le-groupe-kymos\/#primaryimage"},"image":{"@id":"https:\/\/kymos.com\/fr\/news\/kymos-et-prolytic-fusionnent-pour-former-le-groupe-kymos\/#primaryimage"},"thumbnailUrl":"https:\/\/kymos.com\/wp-content\/uploads\/2021\/11\/2020-09-28-Kymos-and-Prolytic-merge_srt-e1658232445349.png","datePublished":"2020-09-28T08:11:26+00:00","dateModified":"2026-03-04T20:10:26+00:00","author":{"@id":"https:\/\/kymos.com\/fr\/#\/schema\/person\/264c93ce9dcf43caa9d634aeafab965c"},"description":"Kymos S.L. et Prolytic GmbH annoncent la r\u00e9ussite d\u2019une fusion strat\u00e9gique visant \u00e0 int\u00e9grer Prolytic au sein de Kymos Group.","breadcrumb":{"@id":"https:\/\/kymos.com\/fr\/news\/kymos-et-prolytic-fusionnent-pour-former-le-groupe-kymos\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/kymos.com\/fr\/news\/kymos-et-prolytic-fusionnent-pour-former-le-groupe-kymos\/"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/kymos.com\/fr\/news\/kymos-et-prolytic-fusionnent-pour-former-le-groupe-kymos\/#primaryimage","url":"https:\/\/kymos.com\/wp-content\/uploads\/2021\/11\/2020-09-28-Kymos-and-Prolytic-merge_srt-e1658232445349.png","contentUrl":"https:\/\/kymos.com\/wp-content\/uploads\/2021\/11\/2020-09-28-Kymos-and-Prolytic-merge_srt-e1658232445349.png","width":900,"height":494,"caption":"Kymos and Prolytic"},{"@type":"BreadcrumbList","@id":"https:\/\/kymos.com\/fr\/news\/kymos-et-prolytic-fusionnent-pour-former-le-groupe-kymos\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/kymos.com\/fr\/"},{"@type":"ListItem","position":2,"name":"Kymos et Prolytic fusionnent pour devenir Kymos Group"}]},{"@type":"WebSite","@id":"https:\/\/kymos.com\/fr\/#website","url":"https:\/\/kymos.com\/fr\/","name":"Kymos Group","description":"Kymos Group","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/kymos.com\/fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Person","@id":"https:\/\/kymos.com\/fr\/#\/schema\/person\/264c93ce9dcf43caa9d634aeafab965c","name":"Joan Puig de Dou","image":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/secure.gravatar.com\/avatar\/263d7ff1c7891f5821a5075a1a362a1e513db5931dc882455e887fe1c1ccf924?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/263d7ff1c7891f5821a5075a1a362a1e513db5931dc882455e887fe1c1ccf924?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/263d7ff1c7891f5821a5075a1a362a1e513db5931dc882455e887fe1c1ccf924?s=96&d=mm&r=g","caption":"Joan Puig de Dou"},"description":"Active in the pharmaceutical marketing for over 30 years President of CataloniaBIO&amp;HealthTech CEO and Qualified Person at Kymos Leader of Kymos team, guaranteeing a trustable, ethical and scientific correct editorial publications. Experience Joan Puig de Dou started his career at Laboratorios Menarini first as scientist later as Qualified Person and finally as Operations General Manager. 2010 he entered Kymos where he became CEO in 2015. 2022 Joan Puig de Dou was elected as president of CataloniaBio&amp;HealthTech to represent the Catalonian biotech industry nationally and internationally. Expertise Joan Puig de Dou has extensive experience in writing scientific content adopting a didactic approach that fits any reader\u2019s level of expertise. He publishes regularely on Kymos\u2019 webpage, social media and in the specialized press. Education He graduated from Universitat de Barcelona as Pharmacist and from IESE Business School\u2019s Programa Diecci\u00f3n General (PDG) Want to know him better? Read his interview in PharmaBoardrooom in January 2019 and more about his presidency of CataloniaBio at Parc Sc\u00edentific de Barcelona.","url":"https:\/\/kymos.com\/fr\/news\/author\/joan-puig-de-dou\/"}]}},"_links":{"self":[{"href":"https:\/\/kymos.com\/fr\/wp-json\/wp\/v2\/posts\/27405","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/kymos.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/kymos.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/kymos.com\/fr\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/kymos.com\/fr\/wp-json\/wp\/v2\/comments?post=27405"}],"version-history":[{"count":5,"href":"https:\/\/kymos.com\/fr\/wp-json\/wp\/v2\/posts\/27405\/revisions"}],"predecessor-version":[{"id":35219,"href":"https:\/\/kymos.com\/fr\/wp-json\/wp\/v2\/posts\/27405\/revisions\/35219"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/kymos.com\/fr\/wp-json\/wp\/v2\/media\/27407"}],"wp:attachment":[{"href":"https:\/\/kymos.com\/fr\/wp-json\/wp\/v2\/media?parent=27405"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/kymos.com\/fr\/wp-json\/wp\/v2\/categories?post=27405"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/kymos.com\/fr\/wp-json\/wp\/v2\/tags?post=27405"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}